

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/893,371	06/27/2001	Primal de Lanerolle	30151/92399	1678	
7	590 07/14/2003				
Kenneth Baro 26118 Research			EXAMINER		
Hayward, CA 94545			YU, MISOOK		
			ART UNIT	PAPER NUMBER	
			1642	/0	
			DATE MAILED: 07/14/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)
		09/893,371	LANEROLLE ET AL.
	Office Action Summary	Examiner	Art Unit
		MISOOK YU, Ph.D.	1642
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet w	vith the correspondence address -
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory perion to reply within the set or extended period for reply will, by state reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a eply within the statutory minimum of thin od will apply and will expire SIX (6) MO tute. cause the application to become A	reply be timely filed inty (30) days will be considered timely. NTHS from the mailing date of this communication. BBANDONED (35 U.S.C. 6 133)
1)⊠	Responsive to communication(s) filed on 3	<u> 0 April 2003</u> .	
2a)⊠		This action is non-final.	
3) <u> </u>	Since this application is in condition for allo closed in accordance with the practice undo on of Claims	wance except for formal ma er <i>Ex parte Quayle</i> , 1935 C	atters, prosecution as to the merits is .D. 11, 453 O.G. 213.
4)🛛	Claim(s) 2.5 and 7 is/are pending in the app	lication.	
	4a) Of the above claim(s) is/are withd	rawn from consideration.	
5)🛛	Claim(s) 5 and 7 is/are allowed.		
6)⊠	Claim(s) 2 is/are rejected.		
7)	Claim(s) is/are objected to.		
8)□	Claim(s) are subject to restriction and	/or election requirement.	
	on Papers		
9) 🗌 🗆	The specification is objected to by the Exami	ner.	
10)[] 1	Γhe drawing(s) filed on is/are: a)□ acc	cepted or b) objected to by	the Examiner.
	Applicant may not request that any objection to		
11) 🔲 7	The proposed drawing correction filed on	is: a)□ approved b)□ o	disapproved by the Examiner.
	If approved, corrected drawings are required in	• •	
	Γhe oath or declaration is objected to by the I	Examiner.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C.	§ 119(a)-(d) or (f).
a)[☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority docume	nts have been received.	
	2. Certified copies of the priority docume	nts have been received in A	Application No
	 Copies of the certified copies of the pr application from the International E ee the attached detailed Office action for a list 	Bureau (PCT Rule 17.2(a)).	
	cknowledgment is made of a claim for domes		
	☐ The translation of the foreign language p		
	cknowledgment is made of a claim for dome		
ttachment		, ,	
) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152) otice to comply.
. Patent and Tra		Action Summary	Part of Paper No. 17

Application/Control Number: 09/893,371

Art Unit: 1642

DETAILED ACTION

Claims 2, 5, and 7 are pending and examined on merits.

Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. 37 CFR 1.821(a) presents a definition for "nucleotide and/or amino acid sequences." The instant application contains an unbranched specifically defined sequence of more than ten nucleotides. Nucleotide and/or amino acid sequences as used in 37 CFR 1.821 through 1.825 are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. Branched sequences are specifically excluded from this definition. Sequences with fewer than four specifically defined nucleotides or amino acids are specifically excluded from this section. "Specifically defined" means those amino acids other than "Xaa" and those nucleotide bases other than "n" defined in accordance with the World Intellectual Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25: Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings inPatent Applications (1998), including Tables 1 through 6 in Appendix 2 (see MPEP § 2422).

Application/Control Number: 09/893,371

Art Unit: 1642

Fig. 3 A has a nucleotide sequence and an amino acid sequence. Both sequences require SEQ ID NOs. The sequence listing filed on 01-09-2002 (Paper No. 5) does not have SEQ ID NOs corresponding to the sequences. This is second time applicant is requested to comply with sequence rule.

Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Claim Objections

The objection to the claims is withdrawn in view of amendment.

Claim Rejections - 35 USC § 112

The rejection under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is moot.

NEW GROUNDS OF REJECTION

Claim Rejections - 35 USC § 112

Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 recites "protein of claim 1" but it is not clear what the metes and bounds are.

Allowable Subject Matter

Claims 5 and 7 are allowed.

Conclusion

Application/Control Number: 09/893,371

Art Unit: 1642

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 703-308-2454. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony C Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Page 5

Misook Yu July 8, 2003

MARY E. MOSHER
PRIMARY EXAMINER
GROUP 1600

pplication No.: 09893371

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 111 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	4 g
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	l
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".	
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entrinto the specification.	у
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support Technical Assistance	
DI FACE DETURN A CORNER OF THE	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY